Smith & Nephew Appoints New Non-Executive Director
Why we think this is neutral
The RNS announcement is a routine Directorate Change, which does not contain any financial or operational updates that would significantly impact the company's performance or outlook.
Key Points
- David King appointed as independent Non-Executive Director
- David has extensive experience in the healthcare and life sciences sectors
- David will serve on the Compliance & Culture and Remuneration Committees
Summary
The healthcare company has appointed a new independent Non-Executive Director to its Board.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, has announced that David King will join the Board as an independent Non-Executive Director effective 1 July 2025. David will serve as a member of the Compliance & Culture and the Remuneration Committees.
GENERAL UPDATE